Resumen

MARTINEZ-CASTRO, Raúl et al. Essential thrombocythaemia. Gac. Méd. Méx [online]. 2022, vol.158, suppl.3, pp.18-27.  Epub 26-Ago-2025. ISSN 2696-1288.  https://doi.org/10.24875/gmm.m22000665.

Essential thrombocythemia (ET) is a chronic Philadelphia-negative myeloproliferative neoplasm (MPN) that has its main involvement in the megakaryopoietic lineage, generating sustained thrombocytosis in peripheral blood and an increase in the number of mature megakaryocytes in the bone marrow. In addition to marked thrombocytosis, it is characterized by increased thrombotic or hemorrhagic risk and the presence of constitutional symptoms. Patients with ET have a low but known risk of disease progression to myelofibrosis and/or acute leukemia. The diagnosis is made based on the 2016 WHO criteria. Currently available treatments for patients with ET are mainly aimed at minimizing the risk of thrombosis and/or bleeding.

Palabras llave : Essential thrombocythemia; Myeloproliferative neoplasms; Thrombocytosis.

        · resumen en Español     · texto en Español     · Español ( pdf )